Filing summary
Entity and period: The supplied filing is Immudyne, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 30, 2016. This does not match the request metadata identifying LifeMD, Inc. The filing reports annual results; standalone fourth-quarter financial figures are not provided.
Business context and financial results
Immudyne makes and sells yeast beta-glucan ingredients and finished nutraceutical and skin-care products. In October 2015 it formed Innate Scientific, a joint venture for finished skin-care products; Immudyne held 33.33% of its economic interest and 51% of its voting interest, and consolidated its results.
| Metric | 2015 | 2014 | Change or context |
|---|---|---|---|
| Revenue | $1,218,862 | $714,158 | Up 71%; 2015 included $139,573 of finished cosmetic product revenue |
| Gross profit / margin | $971,090 / 80% | $541,308 / 76% | Higher sales and margin |
| Operating expenses | $1,233,307 | $1,072,187 | Up 15%, including higher marketing and R&D |
| Operating loss | $262,217 | $530,879 | Loss narrowed |
| Net loss attributable to Immudyne | $61,992 | $460,485 | 2015 also included a $127,261 gain on sale of Adiuvo shares |
| Consolidated net loss | $159,232 | $460,485 | Includes $97,240 loss attributable to noncontrolling interests |
| Cash from operating activities | $(295,124) | $33,439 | 2015 use reflected higher receivables and spending related to Innate, marketing and R&D |
| Cash at year-end | $232,984 | $75,495 | |
| Current assets / current liabilities | $448,471 / $267,481 | $131,473 / $301,519 | 2015 working capital was approximately $181,000 |
| Notes payable at year-end | $100,000 | $27,200 | 2015 balance was a commercial line of credit bearing 11%, due November 1, 2016 |
Financing activities provided $325,352 in 2015, including $178,152 invested in Innate by noncontrolling owners. Investing activities provided $127,261 from the Adiuvo share sale. 2015 revenue was concentrated: the largest customer accounted for 73% of sales and the second largest for 12%.
Changes, outlook, and material risks
- Management expected operating cash and short-term borrowing to fund operations through 2016, while acknowledging possible need for additional equity, debt, or director advances. There is no quantified revenue or earnings guidance.
- The auditor’s report and management disclosures state that substantial doubt exists about the company’s ability to continue as a going concern, citing accumulated losses and negative cash flows. The audited statements contain no adjustments for the outcome of that uncertainty.
- Management cited increased interest in its delivery technology and expected the Innate partnership to contribute meaningfully to 2016 revenue. These are forward-looking expectations, not guarantees.
- Key exposures include reliance on two customers, limited operating scale, financing needs, an illiquid OTC market, and product-claim and manufacturing regulation. The company disclosed it did not maintain product-liability insurance.
- Management concluded disclosure controls and internal control over financial reporting were ineffective and identified material weaknesses, including inadequate segregation of duties, insufficient written accounting and reporting procedures, ineffective period-end controls, and no functioning audit committee. Remediation depended on available funds.
- The company stated that scientific testing cited in the filing had not been reviewed or endorsed by the FDA or another comparable regulator; disease-treatment claims are restricted. The filing also describes related-party transactions, including royalties, loans and office space provided by the CEO.
Important facts to verify
- Confirm issuer identity: the filing is for Immudyne, Inc., not LifeMD, Inc.
- Review the going-concern disclosure, cash runway assumptions, and availability and terms of future financing.
- Check customer concentration, receivable collectability, and the status of the largest customer’s contract, whose initial term was due to expire December 19, 2016.
- Confirm the Innate joint venture’s economics, control arrangements, performance, and any subsequent changes in ownership.
- Reconcile the 2015 reported loss measures, cash flows, and working-capital position against the audited financial statements; do not treat the Adiuvo gain as recurring operating performance.
- Assess the material control weaknesses, governance and related-party arrangements, and whether remediation was completed after the filing date.